Chimeric antigen receptor (CAR) T cells have demonstrated success in treating select hematological malignancies, but their activity in solid tumors has been comparably modest. Challenges specific to treating solid tumors include trafficking and distribution throughout the tumor site, overcoming the immunosuppressive tumor microenvironment (TME), and identifying antigenic targets that are widely expressed and indispensable to tumor biology. In this issue of the JCI, Tian et al. describe the use of bicistronic CAR T cells that target multiple antigens expressed in neuroblastoma to overcome antigenic heterogeneity. Combining this approach with interventions that enhance T cell trafficking and prevent acquired dysfunction in the TME may lead to a long-awaited breakthrough in the clinical implementation of CAR T cells for the treatment of solid tumors.

中文翻译：

---

实体瘤中增强的嵌合抗原受体 T 细胞


嵌合抗原受体 (CAR) T 细胞已在治疗特定血液恶性肿瘤方面取得了成功，但其在实体瘤中的活性相对较低。治疗实体瘤的具体挑战包括整个肿瘤部位的运输和分布、克服免疫抑制肿瘤微环境 (TME)，以及识别肿瘤生物学中广泛表达且不可或缺的抗原靶点。在本期JCI中，Tian 等人。描述了使用双顺反子 CAR T 细胞靶向神经母细胞瘤中表达的多种抗原来克服抗原异质性。将这种方法与增强 T 细胞运输和预防 TME 获得性功能障碍的干预措施相结合，可能会在 CAR T 细胞治疗实体瘤的临床应用中带来期待已久的突破。